



Guide providers to cost-effective, cross-benefit treatment options

Cancer treatments are rapidly increasing in both number and complexity. This leaves employers with the challenge of how to effectively manage cancer medication costs, which are estimated to reach \$246 billion by 2030.¹

This brisk pace for approval of novel, often expensive therapies has had a substantial effect on the standard of care—especially as new clinical data emerges. The U.S. Food and Drug Administration (FDA) approved more than 120 oncology therapies and supportive care drugs in the past five years. And looking ahead, nearly half of experimental drugs in the pipeline target cancer.²



Drives better decisions

The Cancer Guidance Program is an evidence-based utilization management and analytics service that helps ensure quality care while also reducing pharmacy and medical benefit drug costs. This comprehensive solution includes:

- Online portal that helps providers get treatment approvals quickly and easily
- Extensive analytics and reporting to support better oncology care
- Claims-based analysis on cost and quality outcomes for patients on different regimens



Recommends patient-specific treatment plans

The Cancer Guidance Program offers recommendations based on an extensive library with information on more than 60 types of cancer and 2,100 regimens from nationally recognized third parties such as the National Comprehensive Cancer Network (NCCN). Since regimens of the same efficacy can vary widely in cost, the program encourages high-value, low-cost treatment plans.

A decision tool delivers real-time, cross-benefit reviews that encompass:

- Clinical pathways for 23 cancers
- Radiation therapies
- Cancer support medications (i.e., anti-nausea drugs)
- Oral and self-administered injectable therapies



Designed for speed

People don't want to wait to feel better. With this program, most prior authorization requests are decided automatically. In addition, a team of oncology clinicians reviews custom requests for chemotherapy and radiation therapy in peer-to-peer discussions with providers.

- Reduces the administrative burden
- Speeds time to treatment
- Helps providers get paid sooner


40%

of Americans will be diagnosed with cancer in their lifetimes³

18.1M

people in the U.S. are cancer survivors, including 47% who have lived more than 10 years since diagnosis⁴

A faster prior authorization process



of treatment requests are approved immediately via auto-decisioning. The rest go through peer review and outreach, resulting in **~99% approvals⁵**



We're in this together

We developed the Cancer Guidance Program as part of a larger oncology operation, which includes oncology nurses, board-certified oncologists and oncology pharmacists. We have completed more than 800,000 prior authorizations for people living with cancer since the program launched in 2015.



Provider uses an online portal to initiate request for both treatment and prior authorization



Decisioning tool considers coverage options on both pharmacy and medical benefits



Dozens of clinically appropriate therapies are analyzed across both benefits in seconds

- NCCN recommendations
- Preferred drugs, including biosimilars
- Clinical pathway designations



Provider validates highest-quality, lowest-cost recommendation



Full regimen is approved including oncology treatments and supportive care medications on pharmacy and/or medical benefit

Contact your UnitedHealthcare representative for more information

United Healthcare

¹ American Association for Cancer Research: Cancer Care Costs in the United States Are Projected to Exceed \$245 Billion by 2030. [aacr.org/about-the-aacr/newsroom/news-releases/cancer-care-costs-in-the-united-states-are-projected-to-exceed-245-billion-by-2030](https://www.aacr.org/about-the-aacr/newsroom/news-releases/cancer-care-costs-in-the-united-states-are-projected-to-exceed-245-billion-by-2030). Published June 10, 2020. Accessed August 2, 2022.

² UnitedHealthcare. Internal analysis based on Cortellis database. January 2022.

³ American Cancer Society. Cancer Facts & Figures 2021. [cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf). Accessed August 2, 2022.

⁴ National Cancer Institute: Office of Cancer Survivorship Statistics and Graphs. <https://cancercontrol.cancer.gov/ocs/statistics#:~:text=As%20of%20January%202022%2C%20it,approximately%205.4%25%20of%20the%20population.&text=The%20number%20of%20cancer%20survivors,to%2022.5%20million%2C%20by%202032>. Last updated June 27, 2022. Accessed August 9, 2022.

⁵ UnitedHealthcare. Provider auto-approval rate report. 2022.

UnitedHealthcare and the dimensional U logo are trademarks of UnitedHealth Group Incorporated. All other trademarks are the property of their respective owners.